Enhabit (NYSE:EHAB) Updates FY 2024 Earnings Guidance

Enhabit (NYSE:EHAB) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.190-0.290 for the period, compared to the consensus EPS estimate of 0.270. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.1 billion.

Enhabit Stock Down 0.4 %

NYSE EHAB traded down $0.03 during trading hours on Friday, reaching $7.89. 566,776 shares of the company traded hands, compared to its average volume of 315,521. The stock has a market capitalization of $396.71 million, a PE ratio of -3.40 and a beta of 1.84. The company has a 50 day moving average of $7.59 and a two-hundred day moving average of $8.57. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74.

Enhabit (NYSE:EHAB) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to the consensus estimate of $265.99 million. Enhabit had a positive return on equity of 1.61% and a negative net margin of 11.24%. During the same quarter in the previous year, the business earned $0.04 EPS. As a group, equities analysts expect that Enhabit will post 0.26 earnings per share for the current year.

Insider Activity

In related news, Director Jeffrey Bolton acquired 5,000 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were purchased at an average price of $8.01 per share, for a total transaction of $40,050.00. Following the purchase, the director now owns 78,877 shares in the company, valued at $631,804.77. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is currently owned by corporate insiders.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.